SCHEMBL6153753

SCHEMBL6153753

NC(=O)c1cc(Cl)c(NC2CCC(NCC(F)(F)F)CC2)cc1F

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.55
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA3 P07451 1/20 0.39
CA6 P23280 1/20 0.39
CA7 P43166 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
JAK1 P23458 6/20 0.39
JAK2 O60674 5/20 0.39
HPGD P15428 2/20 0.39
GAA P10253 1/20 0.36
HSP90AA1 P07900 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ROCK1 Q13464 1/20 0.35
SCN9A Q15858 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6153755 1.00 ROCK2 (0.55) ROCK2CA1CA2CA3CA6
SCHEMBL6154993 0.89 ROCK2 (0.53) ROCK2CA1CA2CA3CA6
SCHEMBL6154082 0.89 ROCK2 (0.53) ROCK2CA1CA2CA3CA6
SCHEMBL1584269 0.83 ROCK2 (0.80) ROCK2CA1CA2CA3CA6
SCHEMBL6154101 0.83 ROCK2 (0.80) ROCK2CA1CA2CA3CA6
SCHEMBL1584266 0.83 ROCK2 (0.80) ROCK2CA1CA2CA3CA6
SCHEMBL6153960 0.82 ROCK2 (0.50) ROCK2CA1CA2CA3CA6
SCHEMBL6155092 0.80 ROCK2 (0.48) ROCK2CA1CA2CA3CA6
SCHEMBL6154956 0.79 ROCK2 (0.58) ROCK2CA1CA2CA3CA6
SCHEMBL6153508 0.73 ALDH1A1 (0.49) ROCK2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050182040-A1 Benzamide derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-18 US disclosed
EP-1500643-A1 BENZAMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182040-A1 Benzamide derivatives ROCK1, ROCK2, NHERF1 ROCK2 2/4885CA1 4477/4885CA2 240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.